紫杉类新辅助治疗人表皮生长因子受体2阳性乳腺癌的近期疗效分析

目的探讨HER-2阳性乳腺癌对含紫杉类新辅助化疗的敏感性。方法回顾分析159例HER-2阳性的进展期乳腺癌新辅助化疗疗效，采用X2检验比较蒽环类为主化疗方案（蒽环组）和紫杉类为主化疗方案（紫杉组）病理完全缓解率和化疗有效率的差异。结果葸环组和紫杉组的病理完全缓解率分别为7．4％和25．6％，紫杉组明显高于葸环组（X2=9．658，P=0．002）；化疗有效率分别为85．2％和80．8％，两组间差异无统计学意义（x2=0．550，P=0．458）。结论HER-2阳性的进展期乳腺癌患者选择含紫杉类药物联合化疗方案可取得更好的病理完全缓解率。

Analysis of short-term efficacy of taxane based neoadjuvant chemotherapy in HER-2 positive breast cancer

Objective To investigate the chemosensitivity of HER-2 positive advanced breast cancer patients treated with taxane.Methods The efficiency of neoadjuvant chemotherapy in 159 patients with HER-2 positive breast cancer was retrospectively analyzed.Chi-square test was used to compare pathological complete response(pCR) rate and the effective rate of chemotherapy between anthracycline-based chemotherapy group and taxane-based chemotherapy group.Results pCR rate was 7.4% in anthracycline-based group,significantly higher than 25.6% in taxane-based group(χ2=9.658,P=0.002).The effective rate of chemotherapy was 85.2% in anthracycline-based group,80.8% in taxane-based group,and no statistical difference was presented(χ2=0.550,P=0.458).Conclusion For the patients with HER-2 positive breast cancer,taxane-based chemotherapy regimen can achieve a better PCR rate.